FDA approves first drug for rare erection disorder

The Food and Drug Administration has approved the first drug to treat an unusual condition that causes painful, curved erections in men.

The agency says it approved the biotech drug Xiaflex (ZEE'-a-fleks) to treat Peyronie's (PEHR'-oh-nees) disease, which causes an abnormal bend in the penis during erection. The disease is caused by and can lead to pain and other difficulties during sex.

FDA says the is the first non-surgical treatment for the disease.

Drugmaker Auxilium Pharmaceuticals estimates 5 percent of U.S. men are affected.

The FDA said it is limiting distribution of the drug to certified physicians and health care centers due to serious potential side effects, including injury of the penis. Health care professionals must enroll and complete a before prescribing the drug.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Treatment for painful curved penis shows promise

May 08, 2013

(HealthDay)—Some diseases are especially tough to discuss. When Tony Lee realized that his penis was curving whenever he had an erection—making it painful and difficult for him to have sex—he had no ...

Nexavar approval expanded for common thyroid cancer

Nov 24, 2013

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid ...

Generic aciphex approved to treat chronic heartburn

Nov 08, 2013

(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said Friday.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

10 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.